Skip to main content
. 2020 Feb 3;14:457–468. doi: 10.2147/DDDT.S233932

Figure 4.

Figure 4

Metformin (Met) activates the AMPK/mTOR pathway in HUVECs via lncRNA TUG1.

Notes: (A) Transfection efficiency of sg-TUG1 (OE #1,#2,#3). (C) Western blotting was used to detect (B) p-AMPK/AMPK, (D) p-mTOR/mTOR, (E) ATG3, (F) p62, and (G) LC3II/LC3I protein levels after cells were incubated with Met or transfected with OE#1. (H) CCK-8 and (I) wound healing assays were performed to determine the cell viability and migration ability, respectively, after cells were incubated with Met or transfected with OE #1. Data are presented as the mean ± SD. *p < 0.05, **p < 0.01 vs the control group.

Abbreviations: Met, metformin; HUVECs, human umbilical vein endothelial cells; lncRNA, long non-coding RNA; TUG1, taurine up-regulated gene 1; sg-TUG1, single guide taurine up-regulated gene 1; OE, overexpression; CCK-8, cell counting kit-8; SD, standard deviation.